<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071538</url>
  </required_header>
  <id_info>
    <org_study_id>BUILD</org_study_id>
    <secondary_id>KL2RR024154</secondary_id>
    <nct_id>NCT01071538</nct_id>
  </id_info>
  <brief_title>Buprenorphine for Late-Life Treatment Resistant Depression</brief_title>
  <acronym>BUILD</acronym>
  <official_title>Buprenorphine for Late-Life Treatment Resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Reckitt Benckiser LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of this pilot study are to gather data about the safety and clinical effect of
      low-dose buprenorphine in older adults with treatment resistant depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We are recruiting 20 participants for this pilot study. Subjects are recruited from either:

      1) An ongoing study of Late-Life Depression(MH083660; PI: Reynolds) who did not meet research
      response criteria; and 2) community-dwelling individuals, at least 50 years old, who have
      tried at least two FDA-approved antidepressant medications at therapeutic doses each for at
      least 6 weeks, and who are currently in an episode of major depression.

      Overview of intervention: To guide future placebo-controlled work, at this preliminary stage
      of research we will collect data about both buprenorphine (BUP) 1) augmentation
      pharmacotherapy, and 2) monotherapy. Subjects recruited from the community will have the
      buprenorphine prescribed as augmentation to any currently prescribed antidepressant
      medication.

      BUP 0.2 mg will be used for the first week. The first dose will be administered at the clinic
      under the supervision of the PI. Because peak plasma levels occur 60 minutes after ingestion,
      subjects will be re-assessed after 1 hour for safety. Participants will be seen weekly for
      eight weeks to assess progress and monitor intervention-emergent side effects. Dosing
      increases will be guided by antidepressant response (e.g., continued MADRS scores &gt; 10 will
      trigger an increase dose of BUP) and our protocolized use of the Frequency, Intensity, and
      Burden of Side Effect Rating (FIBSER) Scale score. For example, a score of 5 to 7 on the
      FIBSER will trigger additional assessment of side effects and require justification for
      increasing the dose, while a score of &gt; 7 will signal no increase in dose, although specific
      side effects should be reviewed in detail before a final determination, including review if
      the UKU Side Effects Rating Scale.

      We will increase the dose by 0.2 mg/week up to 1.6 mg/day based on MADRS and FIBSER scores.
      Every time the dose is increased, the first ingestion of the higher dose will be monitored in
      the clinic as described above.

      Subjects will participate in the project at the Late-Life Depression Clinic on the 7th Floor
      of Bellefield Tower. Subjects will complete paper and pencil and clinician-administered
      psychiatric assessments before receiving the first dose of buprenorphine and at all
      subsequent visits. After the first ingestion and all subsequent first ingestions of higher
      doses of BUP, subjects will remain in the clinic for 60 minutes after ingestion and be
      re-assessed for the emergence of side effects and have vital signs re-checked. The duration
      of the first visit will be approximately 2.5 hours. If subsequent visits require observed
      ingestion of buprenorphine, they will last about 1.75 hours. If subsequent visits do not
      require observed ingestion of buprenorphine, these visits will last 30-45 minutes.

      Prior to the first ingestion, the first ingestion of subsequent higher doses, and at study
      end, subjects will complete a 15 minute battery of computerized neuropsychological tests
      assessing reaction time and attention. These tests will be repeated 60 minutes after the
      ingestion. Prior to the first ingestion and after discontinuation of the buprenorphine,
      memory will be assessed with the Hopkins Verbal Learning Test (HVLT). The HVLT takes about 10
      minutes to complete.

      The discontinuation phase will occur during weeks 9-12. To minimize the risk of withdrawal
      symptoms, we will discontinue the buprenorphine slowly by reducing the dose to 0.4 mg/day for
      7 days, then 0.2 mg/day every other day for 7 days, and then stop the buprenorphine. We will
      see subjects weekly over these four weeks.

      The final visit will occur at week 16. This will be a telephone check in of mood and
      functioning. This call will take about 15-20 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>measure of depression severity theoretical scale range 0-60 Lower values represent better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Blood Pressure- systolic and diastolic 140/90 or lower is considered normal and indicates a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>UKU Side Effect Rating Scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>measure of side effects 46 items with scores of 0,1,2,3 possible. Theoretical range 0-138 Lower scores indicate fewer side effects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Heart Rate (Beats per minute) 60-100 beats per minute is considered normal lower heart rate represent healthier outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Symptom Inventory -- Anxiety Subscale</measure>
    <time_frame>8 weeks</time_frame>
    <description>measure of anxiety Lower numbers indicate better outcome Theoretical Range 0-2.4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Affect Scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>Positive Affect Score: Scores can range from 10 - 50, with higher scores representing higher levels of positive affect.
Negative Affect Score: Scores can range from 10 - 50, with lower scores representing lower levels of negative affect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Numeric Rating Scale (20 Item)</measure>
    <time_frame>8 weeks</time_frame>
    <description>measure of average physical pain score range 0-20 Higher scores indicate worse outcome</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.</description>
    <arm_group_label>Buprenorphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;/= 50 years

          -  Major depressive disorder

          -  Non-responder to at least 2 FDA-approved antidepressants prescribed at a therapeutic
             dose, each for at least 6 weeks, or is a depression non-responder from an ongoing
             study of late-life depression at our research clinic.

        Exclusion Criteria:

          -  Concomitant use of strong or moderate CYP3A4 inhibitor.

          -  Refusal to stop all opioids.

          -  Refusal to discontinue all alcohol.

          -  Refusal to discontinue benzodiazepines other than the equivalent of lorazepam 2 mg/day
             prescribed at a stable dose for at least the past 2 weeks.

          -  Hepatic impairment (AST/ALT &gt; 1.5 times upper normal.

          -  Lung disease requiring supplemental oxygen.

          -  Estimated creatinine clearance &lt;30 mL/min.

          -  Inability to provide informed consent.

          -  Depressive symptoms not severe enough (i.e., MADRS &lt; 10) at the baseline assessment.

          -  Dementia.

          -  Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective
             disorder, schizophreniform disorder, delusional disorder, or current psychotic
             symptoms.

          -  Abuse of or dependence on alcohol or other substances within the past 3 months.

          -  Meets criteria for history of abuse or dependence upon opioids.

          -  High risk for suicide.

          -  Contraindication to buprenorphine.

          -  Inability to communicate in English.

          -  Non-correctable clinically significant sensory impairment.

          -  Unstable medical illness.

          -  Subjects taking psychotropic medications that cannot be safely tapered and
             discontinued prior to study initiation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordan F Karp, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Psychiatric Institute and Clinica, University of Pittsburgh School of Medicine</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://buprenorphine.samhsa.gov/</url>
    <description>Information about buprenorphine</description>
  </link>
  <link>
    <url>http://www.ADAPTstudy.com</url>
    <description>This link describes our other work with late-life depression at our NIH-funded research clinic in Pittsburgh, PA</description>
  </link>
  <reference>
    <citation>Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr, Jones RM, Portoghese PS, Carlezon WA Jr. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther. 2003 Apr;305(1):323-30.</citation>
    <PMID>12649385</PMID>
  </reference>
  <reference>
    <citation>Nyhuis PW, Gastpar M, Scherbaum N. Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J Clin Psychopharmacol. 2008 Oct;28(5):593-5. doi: 10.1097/JCP.0b013e31818638a4.</citation>
    <PMID>18794671</PMID>
  </reference>
  <reference>
    <citation>Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995 Feb;15(1):49-57.</citation>
    <PMID>7714228</PMID>
  </reference>
  <reference>
    <citation>Emrich HM, Vogt P, Herz A. Possible antidepressive effects of opioids: action of buprenorphine. Ann N Y Acad Sci. 1982;398:108-12.</citation>
    <PMID>6760767</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <results_first_submitted>January 7, 2016</results_first_submitted>
  <results_first_submitted_qc>February 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2016</results_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Jordan F. Karp</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Depressive Disorder, Major</keyword>
  <keyword>Late-Life Depression</keyword>
  <keyword>Geriatrics</keyword>
  <keyword>Buprenorphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Buprenorphine</title>
          <description>Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.
Buprenorphine: Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Buprenorphine</title>
          <description>Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.
Buprenorphine: Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.7" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Montgomery Asberg Depression Rating Scale</title>
        <description>measure of depression severity theoretical scale range 0-60 Lower values represent better outcome</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.
Buprenorphine: Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery Asberg Depression Rating Scale</title>
          <description>measure of depression severity theoretical scale range 0-60 Lower values represent better outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Pressure</title>
        <description>Blood Pressure- systolic and diastolic 140/90 or lower is considered normal and indicates a better outcome.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.
Buprenorphine: Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure</title>
          <description>Blood Pressure- systolic and diastolic 140/90 or lower is considered normal and indicates a better outcome.</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.5" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>UKU Side Effect Rating Scale</title>
        <description>measure of side effects 46 items with scores of 0,1,2,3 possible. Theoretical range 0-138 Lower scores indicate fewer side effects</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.
Buprenorphine: Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>UKU Side Effect Rating Scale</title>
          <description>measure of side effects 46 items with scores of 0,1,2,3 possible. Theoretical range 0-138 Lower scores indicate fewer side effects</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Symptom Inventory -- Anxiety Subscale</title>
        <description>measure of anxiety Lower numbers indicate better outcome Theoretical Range 0-2.4</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.
Buprenorphine: Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Symptom Inventory -- Anxiety Subscale</title>
          <description>measure of anxiety Lower numbers indicate better outcome Theoretical Range 0-2.4</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Affect Scale</title>
        <description>Positive Affect Score: Scores can range from 10 – 50, with higher scores representing higher levels of positive affect.
Negative Affect Score: Scores can range from 10 – 50, with lower scores representing lower levels of negative affect.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.
Buprenorphine: Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Affect Scale</title>
          <description>Positive Affect Score: Scores can range from 10 – 50, with higher scores representing higher levels of positive affect.
Negative Affect Score: Scores can range from 10 – 50, with lower scores representing lower levels of negative affect.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive affect subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative affect subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Numeric Rating Scale (20 Item)</title>
        <description>measure of average physical pain score range 0-20 Higher scores indicate worse outcome</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.
Buprenorphine: Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Numeric Rating Scale (20 Item)</title>
          <description>measure of average physical pain score range 0-20 Higher scores indicate worse outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Heart Rate</title>
        <description>Heart Rate (Beats per minute) 60-100 beats per minute is considered normal lower heart rate represent healthier outcome</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.
Buprenorphine: Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>Heart Rate (Beats per minute) 60-100 beats per minute is considered normal lower heart rate represent healthier outcome</description>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Buprenorphine</title>
          <description>Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.
Buprenorphine: Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jordan F. Karp, MD</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-246-6048</phone>
      <email>karpjf@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

